Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.
Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.
Methotrexate was granted FDA approval on 7 December 1953.
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma
- Conditions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 29
- Registration Number
- NCT00287924
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧Southampton General Hospital, Southampton, England, United Kingdom
🇬🇧Royal Manchester Children's Hospital, Manchester, England, United Kingdom
Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma
- Conditions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- University Hospital, Limoges
- Target Recruit Count
- 40
- Registration Number
- NCT00283985
- Locations
- 🇫🇷
Service d'Hématologie, Evry, France
🇫🇷Département Maladies du Sang, Angers, France
🇫🇷CH Annecy, Annecy, France
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00282308
- Locations
- 🇺🇸
Evanston Northwestern Healthcare, Evanston, Illinois, United States
🇺🇸Borgess Research Institute, Kalamazoo, Michigan, United States
🇺🇸Justus Fiechtner MD - PP, Lansing, Michigan, United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors
- Conditions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 50
- Registration Number
- NCT00281905
- Locations
- 🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland
🇬🇧Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
- Conditions
- Interventions
- Biological: filgrastimBiological: anti-thymocyte globulinDrug: cyclophosphamideDrug: busulfanDrug: carmustineDrug: cyclosporineDrug: fludarabine phosphateDrug: methotrexateDrug: cytarabineDrug: mycophenolate mofetilDrug: etoposideDrug: methylprednisoloneDrug: tacrolimusDrug: melphalanProcedure: peripheral blood stem cell transplantationRadiation: radiation therapyProcedure: umbilical cord blood transplantation
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 200
- Registration Number
- NCT00281879
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- Biological: alemtuzumabBiological: anti-thymocyte globulinBiological: filgrastimBiological: rituximabBiological: therapeutic allogeneic lymphocytesDrug: busulfanDrug: cyclophosphamideDrug: cyclosporineDrug: fludarabine phosphateDrug: methotrexateDrug: mycophenolate mofetilProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT00281983
- Locations
- 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪University Hospital of Leipzig, Leipzig, Germany
🇩🇪Klinikum der Universitaet Regensburg, Regensburg, Germany
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2013-12-19
- Target Recruit Count
- 150
- Registration Number
- NCT00278278
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis
- Conditions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Histiocyte Society
- Target Recruit Count
- 376
- Registration Number
- NCT00276757
- Locations
- 🇬🇧
Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, England, United Kingdom
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 600
- Registration Number
- NCT00275106
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧Royal Manchester Children's Hospital, Manchester, England, United Kingdom
🇩🇪Kinderklinik, Giessen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.